Showing results (581-590 of 627) with videos related to

Sort By:
Pageof 63
Journal of the American Society of Nephrology : JASN|May 2, 2020
Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized TrialMeg J Jardine, Zien Zhou, Kenneth W Mahaffey, et al.
Nature Medicine|May 25, 2024
IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trialGlenn M Chertow, Anna Marie Chang, G Michael Felker, et al.
Circulation|April 22, 2018
Prognostic Significance of Nuisance Bleeding in Anticoagulated Patients With Atrial FibrillationEmily C O'Brien, DaJuanicia N Holmes, Laine E Thomas, et al.
JAMA Cardiology|September 10, 2025
Approach to the Postmarket Evaluation of Consumer Wearable TechnologiesKrishna Pundi, Sanjeev Bhavnani, Clark Seninger, et al.
Cardiovascular Drugs and Therapy|July 24, 2017
Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics ConferenceThomas J Povsic, Rob Scott, Kenneth W Mahaffey, et al.
American Heart Journal|December 3, 2014
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trialGregory G Schwartz, Laurence Bessac, Lisa G Berdan, et al.
The New England Journal of Medicine|November 8, 2018
Alirocumab and Cardiovascular Outcomes after Acute Coronary SyndromeGregory G Schwartz, P Gabriel Steg, Michael Szarek, et al.
Kidney International|October 1, 2020
International consensus definitions of clinical trial outcomes for kidney failure: 2020Adeera Levin, Rajiv Agarwal, William G Herrington, et al.
Circulation|November 6, 2022
Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled TrialSean D Pokorney, Glenn M Chertow, Hussein R Al-Khalidi, et al.
The New England Journal of Medicine|April 17, 2019
Canagliflozin and Renal Outcomes in Type 2 Diabetes and NephropathyVlado Perkovic, Meg J Jardine, Bruce Neal, et al.
Pageof 63